ES2132121T3 - Procedimiento para la purificacion de inhibidores de la hmg-coa reductasa. - Google Patents

Procedimiento para la purificacion de inhibidores de la hmg-coa reductasa.

Info

Publication number
ES2132121T3
ES2132121T3 ES92908427T ES92908427T ES2132121T3 ES 2132121 T3 ES2132121 T3 ES 2132121T3 ES 92908427 T ES92908427 T ES 92908427T ES 92908427 T ES92908427 T ES 92908427T ES 2132121 T3 ES2132121 T3 ES 2132121T3
Authority
ES
Spain
Prior art keywords
hmg
purification
inhibitors
procedure
coa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92908427T
Other languages
English (en)
Inventor
Peter N Haytko
Arthur S Wildman Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24683910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2132121(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2132121T3 publication Critical patent/ES2132121T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/322—Normal bonded phase
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UN PROCESO PARA LA PURIFICACION DE UN INHIBIDOR DE REDUCTASA HMG-COA QUE EMPLEA UNA CROMATOGRAFIA LIQUIDA DE ALTA PRESTACION PREPARATORIA ASI COMO UNA COMPOSICION FARMACEUTICA QUE COMPRENDE EL INHIBIDOR DE REDUCTASA HMG-COA Y PORTADOR FARMACEUTICAMENTE ACEPTABLE.
ES92908427T 1991-03-13 1992-03-09 Procedimiento para la purificacion de inhibidores de la hmg-coa reductasa. Expired - Lifetime ES2132121T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/668,831 US5202029A (en) 1991-03-13 1991-03-13 Process for purification of hmg-coa reductase inhibitors

Publications (1)

Publication Number Publication Date
ES2132121T3 true ES2132121T3 (es) 1999-08-16

Family

ID=24683910

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92908427T Expired - Lifetime ES2132121T3 (es) 1991-03-13 1992-03-09 Procedimiento para la purificacion de inhibidores de la hmg-coa reductasa.

Country Status (9)

Country Link
US (1) US5202029A (es)
EP (1) EP0578723B1 (es)
JP (1) JPH06506210A (es)
AT (1) ATE180986T1 (es)
CA (1) CA2104232A1 (es)
DE (1) DE69229393D1 (es)
ES (1) ES2132121T3 (es)
GR (1) GR3030446T3 (es)
WO (1) WO1992016276A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308479A (en) * 1989-05-26 1994-05-03 Isamu Iwai Sewage disposal apparatus employing circulating filter media
DE4414537A1 (de) * 1994-04-26 1995-11-02 Klinge Co Chem Pharm Fab Kombinationspräparate mit einem Gehalt an einem p-Oxybenzoesäurederivat und einem HMG-CoA-Reduktase-Hemmer
SI9800046A (sl) * 1998-02-18 1999-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
US7141602B2 (en) * 1998-09-18 2006-11-28 Lek Pharmaceuticals D.D. Process for obtaining HMG-CoA reductase inhibitors of high purity
SI20072A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
WO2001030773A2 (en) 1999-10-27 2001-05-03 Merck & Co., Inc. Lactonization process
YU39102A (sh) 1999-11-30 2006-01-16 Biogal Gyogyszergyar Rt Postupak dobijanja statina iz fermentacione smeše
IL150187A0 (en) * 1999-12-14 2002-12-01 Biogal Pharmaceutical Co Ltd Novel forms of pravastatin sodium
HRP20020683A2 (en) 2000-02-24 2004-12-31 Biogal Gyogyszergyar Method of purifying a fermentation broth
CA2402061A1 (en) * 2000-03-03 2001-09-13 Vilmos Keri A process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities
EP1192963A4 (en) * 2000-04-05 2004-08-25 Toray Industries ADSORBENTS FOR PROTEINS OF THE HIGH MOBILITY PROTEIN AND PILLAR GROUP FOR CLEANING BODY LIQUIDS
CN1468098A (zh) * 2000-10-05 2004-01-14 �ݰ¸Ƕ�ҩ�����޹�˾ 基本上无普伐他汀内酯和表普伐他汀的普伐他汀钠和包含普伐他汀钠的组合物
US20050215636A1 (en) * 2000-10-05 2005-09-29 Vilmos Keri Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
US6936731B2 (en) * 2000-10-05 2005-08-30 TEVA Gyógyszergyár Részvénytársaság Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
JP4037898B2 (ja) * 2003-06-18 2008-01-23 テバ ファーマシューティカル インダストリーズ リミティド フルバスタチンナトリウム結晶形ｘｉｖ、ｌｘｘｉｉｉ、ｌｘｘｉｘ、ｌｘｘｘ及びｘｘｘｖｉｉ型、それらの調製方法、それらを含有する組成物及びそれらの使用方法
CA2546701C (en) * 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
DE602004017461D1 (de) 2003-11-24 2008-12-11 Teva Gyogyszergyar Zartkoeruen Verfahren zur reinigung von pravastatin
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
ES2239533B1 (es) * 2004-03-01 2006-12-16 Ercros Industrial, S.A. Procedimiento para la obtencion de compactina.
WO2006035295A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Process for the purification of lovastatin
US7612203B2 (en) * 2005-02-22 2009-11-03 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
WO2009078033A2 (en) * 2007-12-18 2009-06-25 Themis Medicare Limited Isolation and recovery of simvastatin in lactone form or in the form of an acid salt from the harvested fermentation broth
CN102625705B (zh) 2009-04-08 2015-05-06 南洋理工学院 包含他汀类药物的植物提取物及其制备技术和用途
CN102043030A (zh) * 2009-10-22 2011-05-04 北京万全阳光医学技术有限公司 一种用高效液相色谱法测定烟酸辛伐他汀缓释片有关物质的方法
EP2590722A4 (en) * 2010-07-07 2015-06-24 Ironstone Separations Inc TIMING PROCEDURE
EP2597092A1 (en) 2011-11-24 2013-05-29 Sterling Biotech Limited A process for purification of lovastatin
CN112657231B (zh) * 2020-12-24 2022-06-10 西安蓝晓科技新材料股份有限公司 一种三七总皂苷的提纯工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS58140024A (ja) * 1982-02-15 1983-08-19 Eisai Co Ltd セクレチンの精製方法
US4833258A (en) * 1987-02-17 1989-05-23 Merck & Co., Inc. Intermediates useful in the preparation of HMG-COA reductase inhibitors
US4719229A (en) * 1987-05-13 1988-01-12 Merck & Co., Inc. Antihypercholesterolemic agents
US4778600A (en) * 1987-06-17 1988-10-18 Dow Corning Corporation Liquid chromatography dual zone packing materials
US4997755A (en) * 1988-04-15 1991-03-05 Merck & Co., Inc. HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455)
US5099035A (en) * 1989-02-27 1992-03-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5102911A (en) * 1989-06-09 1992-04-07 Merck & Co, Inc. 4-Substituted HMG-CoA reductase inhibitors
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
US4997849A (en) * 1989-06-23 1991-03-05 Merck & Co., Inc. Microbial transformation of simvastatin
US5089523A (en) * 1990-05-11 1992-02-18 E. R. Squibb & Sons, Inc. Fluorinated derivatives of mevinic acids

Also Published As

Publication number Publication date
GR3030446T3 (en) 1999-09-30
EP0578723A4 (en) 1994-06-22
JPH06506210A (ja) 1994-07-14
EP0578723A1 (en) 1994-01-19
CA2104232A1 (en) 1992-09-14
DE69229393D1 (de) 1999-07-15
WO1992016276A1 (en) 1992-10-01
US5202029A (en) 1993-04-13
ATE180986T1 (de) 1999-06-15
EP0578723B1 (en) 1999-06-09

Similar Documents

Publication Publication Date Title
ES2132121T3 (es) Procedimiento para la purificacion de inhibidores de la hmg-coa reductasa.
BR9506535A (pt) Inibidores de metaloproteinases
TW269682B (es)
EA199800302A1 (ru) Способ получения дифторметана
BR9401952A (pt) União para conexão rápida estanque de tubulações
ES2134910T3 (es) Sintesis de bisindolilmaleimidas.
EA199900221A1 (ru) Синтез бисиндолилмалеимидов
PT545511E (pt) Processo para a preparacao de tetraazamacrociclos mono-n-substituidos
NO306297B1 (no) FremgangsmÕte for fremstilling av HIV-proteaseinhibitorer
DK624088D0 (da) Fremgangsmaade til kontinuerlig forgaering af carbonhydratholdige medier ved hjaelp af bakterier
DE69008277D1 (de) 7-Subsituierte HMG-CoA-Reduktase-Inhibitoren.
NO921806L (no) Fremgangsmaate ved hydrodesyklisering av gassolje
DE69301555D1 (de) Hochdruckverflüssiger
BR9104604A (pt) Dispositivo para expansao de gases liquefeitos
SV1997000031A (es) Nuevo procedimiento eficaz y de alta selectividad enantiomerica para la producccion de ciclopentano-beta- aminoacidos enantiomericamente puros. ref. lea 31688-sv
BR9104605A (pt) Dispositivo para expansao de gases liquefeitos
NO931875D0 (no) Anordning ved blendfri belysning av flater
NO923862D0 (no) Inhibitorer for hmg-coa-reduktase
KR940023763U (ko) 대상체의 위치 발견용 페이지 장치
DE69025817D1 (de) 3-Keto-HMG-CoA Reduktase-Inhibitoren
KR950011967U (ko) 자동차의 클러치 유격조정용 푸쉬로드(push rod)
ES2099621T3 (es) Procedimiento para producir un derivado de imidazol.
KR950015443U (ko) 전자렌지용 고압 트랜스
KR970027812U (ko) 인히비터 스위치 위치고정용 지그
ES1021570Y (es) Pieza de armario para estructuras de aluminio.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 578723

Country of ref document: ES